Found: 4
Select item for more details and to access through your institution.
Population pharmacokinetic and exposure‐response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis.
- Published in:
- British Journal of Clinical Pharmacology, 2023, v. 89, n. 10, p. 3139, doi. 10.1111/bcp.15803
- By:
- Publication type:
- Article
Optimal planning of phase II/III programs for clinical trials with multiple endpoints.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 5, p. 437, doi. 10.1002/pst.1861
- By:
- Publication type:
- Article
Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 4, p. 994, doi. 10.1002/cpt.1671
- By:
- Publication type:
- Article
Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3222
- By:
- Publication type:
- Article